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Objectives This study tested the hypothesis that acute administration of the xanthine oxidase (XO) inhibitor allopurinol
improves cardiac high-energy phosphate concentrations in human heart failure (HF) and increases the rate
of adenosine triphosphate (ATP) synthesis through creatine kinase (CK), the primary myocardial energy
reserve.
Background Studies of patients and animal models implicate impaired myocardial high-energy phosphate availability in HF.
The XO reaction is a critical terminal step in ATP and purine degradation and an important source of reactive
oxygen species. Thus, XO inhibition is a potentially attractive means to improve energy metabolism in the failing
human heart.
Methods We randomized 16 patients with nonischemic cardiomyopathy in a double-blind fashion to allopurinol (300 mg
intravenously) or placebo infusion, 4-to-1, the latter for purposes of blinding only. The myocardial concentrations
of ATP and creatine phosphate (PCr) and the rate of ATP synthesis through CK (CK flux) were determined by 31P
magnetic resonance spectroscopy.
Results Allopurinol infusion increased mean cardiac PCr/ATP and PCr concentration by 11% (p  0.02), and mean CK
flux by 39% (2.07  1.27 mol/g/s to 2.87  1.82 mol/g/s, p  0.007). Calculated cytosolic adenosine
diphosphate concentration decreased, whereas the free energy of ATP hydrolysis (GATP) increased with allopuri-
nol. The increased CK flux was disproportionate to substrate changes, indicating increased CK enzyme activity.
Conclusions Intravenous administration of the XO inhibitor allopurinol acutely improves the relative and absolute concentra-
tions of myocardial high-energy phosphates and ATP flux through CK in the failing human heart, offering direct
evidence that myofibrillar CK energy delivery can be pharmaceutically augmented in the failing human heart.
(Intravenous Allopurinol in Heart Failure; NCT00181155) (J Am Coll Cardiol 2012;59:802–8) © 2012 by the
American College of Cardiology Foundation
Published by Elsevier Inc. doi:10.1016/j.jacc.2011.10.895Because adenosine triphosphate (ATP) is required for
normal cardiac contractile function, it has long been
hypothesized that inadequate ATP availability may con-
tribute to the contractile dysfunction observed in non-
ischemic chronic heart failure (HF) (1–3). Indirect sup-
port for the hypothesis that the failing heart is “energy
starved” arises from studies showing that abnormalities in
myocardial energy metabolism are observed in nearly
every experimental model of HF and in patients with HF.
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accepted October 19, 2011.It is additionally supported by observations that common
HF medications including beta-blockers and angiotensin-
converting enzyme inhibitors that improve HF outcomes
and survival (1,3) coincidentally also reduce energetic
demand. Nevertheless, there are currently no approved
HF treatment strategies designed to improve energy
delivery or the coupling between energy delivery and
mechanical function (mechanoenergetic coupling) in the
failing heart.
See page 809
Xanthine oxidase (XO) inhibition is a potentially attrac-
tive strategy for improving energy metabolism and mecha-
noenergetic coupling in HF (4,5). XO is a critical, terminal
reaction in ATP and purine degradation and also an
important source of reactive oxygen species (ROS). There is
evidence of increased myocardial XO activity and ROS in
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include inactivation of sulfhydryl (SH)-containing enzymes.
The creatine kinase (CK) reaction is the prime energy
reserve of the heart (6,7). It reversibly and rapidly transfers
a high-energy phosphoryl group between creatine phos-
phate (PCr) and ATP, and the myofibrillar isoform of the
CK enzyme is particularly sensitive to ROS (8). Thus, a XO
inhibitor (XOI) could enhance the energetic profile of the
failing heart (9) by limiting the degradation of ATP and loss
of adenine nucleosides and/or by attenuating the decrease in
CK capacity and thereby increasing the rate of ATP
generation through myofibrillar CK.
Allopurinol is an XOI approved for the clinical treatment
of gout. However, it also improved mechanoenergetic cou-
pling in a canine paced tachycardia model of HF (10) and
acutely reduced myocardial oxygen consumption without
impairing contractile function in patients with dilated car-
diomyopathy (11). There are, however, few direct studies of
the effects of XO inhibition on myocardial energy metabo-
lism and none in the human heart.
31P magnetic resonance spectroscopy (MRS) is the only
method capable of noninvasively measuring myocardial
high-energy phosphate metabolites in the human heart.
31P MRS studies have identified significant reductions in
cardiac PCr/ATP in HF patients (12–14). Furthermore,
recent magnetization transfer MRS techniques capable of
measuring the rate of ATP production through CK in the
human heart have documented 50% to 70% reductions in
the rate of ATP synthesis through CK in several common
forms of HF (15–17). In animal models, chronic XO
inhibition improved cardiac PCr/ATP in murine myo-
cardial infarction (18), and acute XO inhibition increased
PCr/ATP and total PCr content in pacing-induced
canine HF (9); however, the energetic effects of XOI have
never been documented in human HF. Moreover, there
have been no direct studies of the effects of XO inhibition
or any other intervention on the rate of ATP synthesis
through CK in the failing human heart.
Therefore, the purpose of this study was to measure
directly both the myocardial concentrations of high-energy
phosphates and the rate of ATP synthesis through CK in
patients with HF using noninvasive 31P MRS. We tested
the hypothesis that acute administration of allopurinol
improves cardiac high-energy phosphate metabolism in the
failing human heart by increasing the rate of ATP produc-
tion through CK (CK flux).
Methods
Study patients. The study was approved by the Johns
Hopkins Institutional Review Board for Human Investiga-
tion. All subjects gave informed consent after receiving an
explanation of the study and protocol. Sixteen patients with
New York Heart Association functional class II or higher
HF symptoms, a left ventricular ejection fraction 40%,
and nonischemic cardiomyopathy diagnosed by either acardiac catheterization demon-
strating no significant coronary
artery disease (n  13), a nega-
tive stress perfusion study in low-
risk patients (n  2), or onset of
cardiomyopathy during preg-
nancy at age younger than 25
years (n 1) were enrolled. Car-
diac magnetic resonance imag-
ing/MRS was performed using a
General Electric 1.5-T magnetic
resonance imaging/MRS system
(General Electric Healthcare
Technologies, Waukesha, Wis-
consin) in subjects before and 15
min after completion of intrave-
nous infusion of the study drug,
either allopurinol (Aloprim 300
mg) or placebo (equivalent 50 ml
dose of 5% dextrose). The study
drug allocation was randomized
in a 4-to-1 ratio by the research
pharmacy with all investigators
and subjects blinded to the ran-
domization. Because the critical
comparison was the metabolic
effect of allopurinol compared
with baseline in the same patient, equal randomization was
not required and a smaller placebo group was used for
purposes of blinding only.
Study protocol. MRS studies were performed with sub-
jects oriented prone on a 6.5-cm 31P receive/25-cm 31P
transmit surface coil set, as previously described (15,17,19).
The complete patient cardiac MRS protocol is described in
the Online Appendix but includes the following steps:
1. Conventional scout magnetic resonance imaging for
positioning
2. Acquisition of the 4 31P 4-angle saturation transfer
method datasets localized by 1-dimensional chemical
shift imaging to measure CK flux
3. Acquisition of a fifth 31P 1-dimensional chemical shift
imaging set with saturation turned off for phosphate
metabolite quantification
4. Acquisition of a sixth 1H 1-dimensional chemical shift
imaging data set for metabolite quantification
5. Infusion of allopurinol or placebo
6. Repetition of step 2 to obtain a second measurement
of CK flux (15), followed by removal of the patient
from the magnet
7. Repetition of steps 3 and 4 with a 0.15-mol/l inor-
ganic phosphate reference phantom to measure the
metabolite concentrations
ata analysis. MRS DATA. MRS data were analyzed in
blinded fashion by one of the authors (P.A.B.), without
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code was broken. The pseudo first-order CK reaction rate
constant (kf) and the myocardial PCr and ATP concentra-
tions (PCr and ATP concentrations) were calculated as
previously described (15–17,20). The forward CK flux or
Clinical Characteristicsof the Allopurinol Group (n  13)Table 1 Clinical Characteristicsof the Allopurinol Group (n  13)
Age, yrs 47.8 12.9
Male 9 (69.2)
LV ejection fraction, % 18.1 6.0
NYHA functional class
II 10 (76.9)
III 3 (23.1)
Hypertension 4 (30.8)
Diabetes mellitus 0 (0)
Medications
ACE inhibitor or ARB 13 (100)
Beta-blocker 9 (69.2)
Loop diuretic 9 (69.2)
Aldosterone blocker 7 (53.9)
Digitalis 3 (23.1)
Statin 5 (38.5)
Aspirin 6 (46.2)
Values are mean  SD or n (%).
ACE  angiotensin-converting enzyme; ARB  angiotensin receptor blocker; LV  left ventricular;
YHA  New York Heart Association.
Figure 1 MRS Study With Corresponding Spectra
Annotated scout magnetic resonance image (A) showing 4 locations (no. 1 to 4) o
4) of a 45-year-old man with dilated cardiomyopathy and New York Heart Associati
MRS protocol without chemical selective irradiation for quantification of metabolite
applied to the -ATP resonance (orange arrow), and at the control location (green
(D) Spectra from step 6 of the MRS protocol following, in this case, allopurinol inf
part, by a greater decrease in the PCr signal with saturation (blue line). All spectr
MRS  magnetic resonance spectroscopy; PCr  creatine phosphate; ppm  parrate of ATP synthesis through CK is given by the product
(kf.PCr concentration), in mol/g wet weight/s (15–17).
Intracellular-free ADP concentration and the free-energy
change of ATP hydrolysis (GATP [kJ/mol]) were deter-
mined as previously described (15,21). The theoretically
predicted rate of the CK equation was calculated as previ-
ously reported (15,22) and detailed in the Online Appendix.
Statistical analyses. Data analyses were performed using
STATA version 11.0 (StataCorp, College Station, Texas).
Data are displayed as mean  SD. Two-sided paired t tests
ere used to compare each subject’s pre- and post-infusion
ariables. A p value 0.05 was considered statistically
ignificant.
esults
he characteristics of the patient cohort are summarized in
able 1. Intravenous infusion of allopurinol (300 mg) had
o significant hemodynamic effects (heart rate pre-infusion,
5.8 12 beats/min vs. 74.7 13 beats/min post-infusion,
p  0.49; systolic blood pressure pre-infusion, 131.7  28
mm Hg vs. 134.6  24 mm Hg post-infusion, p  0.68;
rate pressure product pre-infusion 9,817 2,484 beats-mm Hg/
in vs. 10,358  3,380 beats-mm Hg/min post-infusion,
 0.35).
Representative myocardial 31P magnetic resonance spec-
ra are shown in Figure 1. Before allopurinol or placebo
spectra acquired from the chest wall (no. 1) and anterior myocardium (nos. 2 to
ctional class III heart failure (B to D). (B) Spectra acquired in step 3 of the
ntrations. (C) Spectra acquired in step 2 with chemical selective irradiation
). The change in height in PCr (red line) is a measure of the forward CK flux.
An increase in CK flux from 0.7 mol/g/s to 1.7 mol/g/s is evidenced, in
caled identically. -ATP  -adenosine triphosphate; CK  creatine kinase;
million.f 31P
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PCr and ATP concentrations were 7.6  1.8 mol/g and
4.9  1.3 mol/g, respectively, for all 16 HF subjects.
Likewise, mean kf and CK flux at baseline for all subjects
before administration of study drug were 0.25  0.13 s1
and 1.91  1.19 mol/g/s, respectively, both consistent
ith previously reported values in patients with nonischemic
ilated cardiomyopathy (15).
Allopurinol infusion in 13 patients increased the mean
ardiac PCr/ATP and PCr concentration by 11%, from
.58  0.41 to 1.75  0.59 (p  0.02) and from 7.31 
.79 mol/g to 8.06  2.40 mol/g (p  0.02), respec-
ively. Mean kf trended higher by 20% (0.28  0.13 vs.
.34  0.14, p  0.054). Importantly, the rate of ATP
ynthesis through CK increased significantly by 39% during
llopurinol infusion, from 2.07  1.27 mol/g/s to 2.87 
.82 mol/g/s (p  0.007) (Table 2, Fig. 2).
There were no changes in cardiac PCr/ATP, PCr con-
centration, or CK flux in the small group who received
placebo.
The observed increases in PCr/ATP and PCr concentration
during allopurinol infusion are associated with energetically
favorable changes in free cytosolic [ADP] and the free energy
of ATP hydrolysis (GATP). Cytosolic free [ADP] decreased
with allopurinol infusion, from 60  24 M to 53  28 M
p  0.05), and mean GATP decreased from 60.4  1.2
J/mol to61.0 1.7 kJ/mol (p 0.05). Note that the more
egative GATP reflects a greater energy release for each
molecule of ATP hydrolyzed (21) with allopurinol infusion.
To test whether the increase in CK flux elicited by
allopurinol is due to differences in the substrates and
reactants driving the CK reaction and/or a change in activity
of the CK enzyme itself (maximum velocity [Vmax]), the
predicted rate of ATP synthesis through CK was calculated
(f pred in Equation 5 in the Online Appendix). The
redicted effect of the observed 11% increase in myocardial
Cr/ATP and 13% decrease in [ADP] is to actually
ecrease the rate of ATP synthesis through CK by 2%.
herefore, the observed 39% increase in the rate of ATP
ynthesis through CK with allopurinol in these HF patients
s attributable to a significant (40%) increase in CK
nzyme activity (Vmax).
In Vivo Myocardial Energetics Including CardiacPCr/ATP, Creatine Phosphate Concentration,Cytos lic ADP, GATP, and ATP Flux Through CK
Table 2
In Vivo Myoc r ial Energetics Including Cardiac
PCr/ATP, Creatine Phosphate Concentration,
Cytosolic ADP, GATP, and ATP Flux Through CK
Baseline After Allopurinol Infusion
Cardiac PCr/ATP 1.58 0.41 1.75 0.59*
PCr concentration, mol/g wet weight 7.3 1.8 8.1 2.4*
ADP concentration, M 60 24 53 28†
GATP, kJ/mol 60.4 1.2 61.0 1.7†
CK flux, mol/g/s 2.07 1.27 2.87 1.82‡
Values are mean  SD. Allopurinol n  13 for all endpoints. *p  0.02 vs baseline. †p  0.05.
‡p  0.007 vs. baseline.ADP adenosine diphosphate; ATP adenosine triphosphate; CK creatine kinase; GATP
free energy of adenosine triphosphate hydrolysis; PCr  creatine phosphate.Discussion
There are at least 4 novel observations in this randomized,
double-blind, uncontrolled study of the acute energetic
effects of intravenous allopurinol infusion in HF patients.
First, the myocardial high-energy phosphate, PCr, is in-
creased significantly, in both absolute (PCr concentration)
and relative (PCr/ATP) terms, by allopurinol infusion in
the failing human heart. Second, in terms of ATP utiliza-
tion, allopurinol acutely results in favorable energetic
changes that include a reduction in cytosolic free ADP
concentration and an increase in the amount of energy
released with each ATP molecule hydrolyzed (GATP).
ndeed, both would significantly reduce the energetic cost of
ontraction. Third, allopurinol increases ATP availability,
he amount of ATP synthesized through CK, the major
yocardial energy reservoir, by almost 40% in the failing
uman heart. This demonstrates that a pharmacologic
ntervention can acutely increase ATP synthesis through
K in the human heart. Fourth, the increase in ATP flux
hrough CK cannot be explained by the changes in PCr and
ther energy metabolite pools and is best explained by an
cute allopurinol-induced increase in CK enzyme activity
Vmax). It is interesting to note that the predicted rate of
ATP flux through CK increases by 35% if the Vmax
measured in failing human hearts is substituted by values
from normal human hearts (7). This suggests that the
observed allopurinol-induced increase in CK flux in failing
hearts is due to near-normalization of CK enzyme activity.
We speculate that allopurinol nearly normalizes CK activity
by attenuating ROS-induced CK inhibition because ROS is
increased in HF and because myofibrillar CK activity is
decreased by ROS in in vitro models (8).
Myocardial energy metabolism is impaired in experimen-
Figure 2 Effect of Allopurinol on ATP Synthesis via CK
The rate of ATP synthesis through cardiac CK (mol/g/s) under baseline and
allopurinol conditions (summary bars represent mean  SD). Abbreviations as
in Figure 1.tal and clinical HF and thus presents a compelling target for
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metabolism and specifically in the CK reaction, the primary
myocardial energy reserve, have been reported in experi-
mental models across many species including mice, ham-
sters, rats, rabbits, pigs, and dogs (3). Reductions in the
cardiac PCr/ATP ratio at rest in HF patients were first
reported approximately 20 years ago (12–14,23) and may
predict cardiovascular mortality (24).
More recently, measures of the rate of ATP transfer via
the CK reaction have become possible in the human
heart, with reductions of 50% to 70% below normal
values reported in failing dilated hearts (15). This re-
ported reduction in ATP flux through CK (15) was
disproportionate to the more modest (10% to 20%)
decrease in resting PCr/ATP and occurred before a
significant reduction in ATP concentration could be
detected in patients with mild to moderate HF symptoms
(15). It was suggested that the magnitude of the reduc-
tion in CK ATP flux could be sufficient to temporally
limit ATP energy delivery during periods of stress or
peak demand in patients with HF (15). Thus, an inter-
vention that significantly enhances ATP delivery to the
myofibrils to better fuel myocardial contraction by im-
proving high-energy phosphate stores (e.g., PCr/ATP,
PCr concentration, or ATP concentration) and/or CK
flux could well represent an important treatment option
for human HF.
The current observations demonstrate that allopurinol
acutely enhances the energetic profile of the failing human
heart by improving both myofibrillar ATP delivery and use.
The significant increase in PCr content with allopurinol
observed here is similar to that observed with a nonpurine
XOI in canine hearts (9). The CK reaction provides a rapid
source of myofibrillar ATP and is believed to serve as a
spatial ATP buffer, enhancing ATP delivery from the sites
of mitochondrial production to the cytosolic sites of ATP
utilization (6,25). The 40% acute allopurinol-induced
increase in the mean rate of ATP synthesized through the
CK reaction should significantly augment both the temporal
and spatial delivery of myofibrillar ATP. Indeed, the rate of
ATP flux through CK with allopurinol here appears to
increase to almost that of healthy human hearts (3.3  0.8
mol/g/s wet weight) (17).
The amount of free energy released from ATP utili-
zation for contractile and other myocellular functions is
also increased acutely by allopurinol in the failing heart.
By maintaining low ADP concentration and inorganic
phosphate concentration, the CK reaction supports a
high phosphorylation potential that maximizes the
amount of energy liberated from the hydrolysis of each
ATP molecule (GATP). Inhibition of CK in rat hearts
owers contractile reserve and free energy release, which,
n turn, limits the Ca2-handling capacity of the sarco-
lasmic reticular Ca2 ATPase (26). An increase in
cytosolic-free ADP concentration is also associated with
diastolic dysfunction, possibly by slowing the rate of Ocross-bridge cycling (27,28). In the current study, calcu-
lated cytosolic-free ADP concentration decreased signif-
icantly by 11% and the mean GATP changed by
0.5 kJ/mol after acute allopurinol administration in
failing human hearts, signifying an increase in the free
energy generated from ATP utilization. Although these
metabolic changes may seem modest, the changes in ATP
flux through CK and GATP, would together result in
n additional 3.8 kJ of energy availability per gram of
yocardium over the course of a day. This could explain
he acute improvement in mechanoenergetic coupling in
he failing human heart reported for allopurinol, whereby
ontractile function is maintained with a lower require-
ent for oxygen consumption (10,11).
Inhibition of XO, a terminal step in purine degradation,
as proposed years ago as a means of preserving high-
nergy phosphates in ischemic hearts (29). Although the
ntracellular milieu during acute severe ischemia differs
ramatically from that in the chronically failing heart, it is
ossible that some of the improvement in energetics ob-
erved here is related in part to allopurinol limiting purine
reakdown. However, given the relatively short time course
f this acute study and the relatively long time for adenine
nd other purine degradation in the failing heart (30), it
eems unlikely that limiting purine degradation could ex-
lain all of the observed acute effects. On the other hand,
O activity and ROS are increased in HF (4,5), which
ould rapidly affect energy metabolism. ROS can directly
nhibit CK by modulating its critical SH groups (31), as
videnced by studies of rat myocardium, suggesting that the
ain adverse effect of ROS in myofibrils is the oxidation of
ssential SH groups of CK, which inactivates the enzyme
8). This decreases the local ATP/ADP ratio and impairs
a2 handling with little or no change in magnesium-
TPase activity (8). The current observation of an acute
ncrease in ATP flux through myofibrillar CK that cannot
e explained by changes in the substrates driving the CK
eaction is consistent with allopurinol acting to reverse such
K inhibition by limiting ROS inactivation of the essential
H groups on myofibrillar CK. The findings lend hope that
reatments such as those limiting ROS or their conse-
uences can acutely improve the impaired myocardial CK
TP supply in human HF (11).
The enthusiasm for long-term XOI therapy in human
F was initially diminished when the OPT-CHF (Oxy-
urinol Therapy for Congestive Heart Failure) trial failed
o demonstrate a benefit based on the composite endpoint
f HF morbidity, mortality, and quality-of-life assess-
ent (31). That trial in symptomatic HF patients com-
ared 600 mg oxypurinol, the active metabolite of allo-
urinol, with placebo over 24 weeks (31). However, the
00 mg oxypurinol may have been inadequate because it
as a bioequivalence of only 81 mg allopurinol (32,33),
hich is often administered in doses of 300 to 600 mg. In
ddition, the decreases in serum uric acid reported in the
PT-CHF trial were less than would be expected for a
m
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retrospective analysis of HF patients with gout demon-
strated improved outcomes in those taking allopurinol,
with a reduction in the risk of HF readmission (adjusted
rate ratio: 0.69; 0.60 to 0.79; p  0.001) and for all-cause
mortality (adjusted rate ratio: 0.74; 0.61 to 0.90; p 
0.001) (34). The clinical trial EXACT-HF (Using Allo-
purinol to Relieve Symptoms in Patients With Heart
Failure and High Uric Acid Levels) is currently enrolling
250 HF patients with an estimated completion date of
May 2012 to compare allopurinol and placebo for com-
bined clinical endpoints, quality of life, and submaximal
exercise capacity (NCT00987415). Thus, the question of
the clinical benefit of long-term allopurinol administra-
tion to patients with HF at therapeutic doses is currently
unresolved and was not an aim of this acute study.
Metabolic strategies to treat heart disease were first
proposed 50 years ago (35,36), and the literature has
been recently reviewed (37,38). Another area where
modest metabolic improvements may be clinically rele-
vant in HF relates to the observation that fatty acid
oxidation is increased in HF but is a less efficient carbon
source than glucose, consuming 11% to 12% more oxygen
per molecule of ATP synthesized (37,39). Thus, strate-
gies to increase glucose use (40) or inhibit fatty acid
oxidation have been pursued to limit “oxygen wastage”
(37). One such inhibitor, trimetazidine, improved left
ventricular ejection fraction and functional class in HF
patients (41).
Study limitations. The limitations of the current study
include the small placebo group sample size and the etio-
logic heterogeneity of the nonischemic cardiomyopathy
group. It is unlikely, however, that these flaws are serious
because the critical analysis relates to the before and after
comparison in the larger allopurinol group and because
etiologic heterogeneity in nonischemic cardiomyopathy oc-
curs commonly in clinical practice.
Conclusions
In summary, this first study demonstrating that allopuri-
nol acutely augments myocardial energy supply via CK
and increases the free energy release from the hydrolysis
of each ATP molecule in HF patients likely provides the
mechanism by which allopurinol improves mechanoener-
getic coupling, decreasing myocardial oxygen consump-
tion while maintaining function in human HF (11).
These observations are important for both evaluating
allopurinol’s potential as a therapeutic agent and demon-
strating a role for noninvasive 31P MRS in assessing the
echanistic consequences of treatments that target en-
rgy supply and use.
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